Special Report: The Lab Kickback Risks of “Freebies”
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
ASCP chief medical officer Ali Brown, MD, FASCP, discusses the highlights of 2023 and ASCP’s plans for supporting its members in 2024.
Though things appeared status quo in 2023, last year may prove to be a turning point for the laboratory industry.
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
Robin Divine, MBA, president and CEO of TriCore Reference Laboratories, discusses key recent developments in the lab industry and predictions for 2024.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.